{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:45:01Z","timestamp":1788306301527,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,3]],"date-time":"2015-01-03T00:00:00Z","timestamp":1420243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s11060-014-1702-0","type":"journal-article","created":{"date-parts":[[2015,1,2]],"date-time":"2015-01-02T15:43:32Z","timestamp":1420213412000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center"],"prefix":"10.1007","volume":"122","author":[{"given":"Filippo","family":"Ceccato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Manara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Emanuelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Milanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Paola","family":"Gardiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Bertorelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Scanarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D\u2019Avella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Occhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Boscaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,3]]},"reference":[{"key":"1702_CR1","volume-title":"World Health Organization classification of tumours: tumours of endocrine organs","year":"2004","unstructured":"De Lellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health Organization classification of tumours: tumours of endocrine organs. IARC, Lyon"},{"issue":"2","key":"1702_CR2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/eje.1.02326","volume":"156","author":"W Saeger","year":"2007","unstructured":"Saeger W, L\u00fcdecke DK, Buchfelder M et al (2007) Pathohistological classification of pituitary tumors: 10\u00a0years of experience with the German pituitary tumor registry. Eur J Endocrinol 156(2):203\u2013216","journal-title":"Eur J Endocrinol"},{"key":"1702_CR3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3171\/2010.8.JNS10290","volume":"114","author":"G Zada","year":"2011","unstructured":"Zada G, Woodmansee WW, Ramkissoon S et al (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336\u2013344","journal-title":"J Neurosurg"},{"key":"1702_CR4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(06)70728-8","volume":"7","author":"S Lim","year":"2006","unstructured":"Lim S, Shahinian H, Maya MM et al (2006) Temozolamide: a novel treatment for pituitary carcinoma. Lancet Oncol 7:518\u2013520","journal-title":"Lancet Oncol"},{"key":"1702_CR5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3171\/jns.2006.105.4.621","volume":"105","author":"CE Fadul","year":"2006","unstructured":"Fadul CE, Kominsky AL, Meyer LP et al (2006) Long term response of pituitary carcinoma to temozolomide. J Neurosurg 105:621\u2013626","journal-title":"J Neurosurg"},{"issue":"3","key":"1702_CR6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/cncr.25413","volume":"117","author":"LV Syro","year":"2011","unstructured":"Syro LV, Ortiz LD, Scheithauer BW et al (2011) Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117(3):454\u2013462. doi: 10.1002\/cncr.25413","journal-title":"Cancer"},{"issue":"6","key":"1702_CR7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2265.2012.04381.x","volume":"76","author":"G Raverot","year":"2012","unstructured":"Raverot G, Castinetti F, Jouanneau E et al (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 76(6):769\u2013775. doi: 10.1111\/j.1365-2265.2012.04381.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1702_CR8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B et al (2009) Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94(1):115\u2013122. doi: 10.1210\/jc.2008-1008","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1702_CR9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J et al (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366(10):914\u2013924. doi: 10.1056\/NEJMoa1105743","journal-title":"N Engl J Med"},{"key":"1702_CR10","author":"S Petersenn","year":"2014","unstructured":"Petersenn S, Bollerslev J, Arafat AM et al (2014) Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. J Clin Pharmacol. doi: 10.1002\/jcph.326","journal-title":"J Clin Pharmacol"},{"key":"1702_CR11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/er.2012-1013","volume":"34","author":"A Beckers","year":"2013","unstructured":"Beckers A, Aaltonen LA, Daly AF et al (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34:239\u2013277","journal-title":"Endocr Rev"},{"key":"1702_CR12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1530\/ERC-12-0322","volume":"20","author":"ML Jaffrain-Rea","year":"2013","unstructured":"Jaffrain-Rea ML, Rotondi S, Turchi A et al (2013) Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer 20:753\u2013766","journal-title":"Endocr Relat Cancer"},{"key":"1702_CR13","doi-asserted-by":"crossref","first-page":"15558","DOI":"10.1073\/pnas.0603877103","volume":"103","author":"NS Pellegata","year":"2006","unstructured":"Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103:15558\u201315563","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1702_CR14","doi-asserted-by":"crossref","first-page":"e1003350","DOI":"10.1371\/journal.pgen.1003350","volume":"9","author":"G Occhi","year":"2013","unstructured":"Occhi G, Regazzo D, Trivellin G et al (2013) A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet 9(3):e1003350. doi: 10.1371\/journal.pgen.1003350","journal-title":"PLoS Genet"},{"issue":"3","key":"1702_CR15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00401-011-0855-6","volume":"122","author":"JT Huse","year":"2011","unstructured":"Huse JT, Nafa K, Shukla N et al (2011) High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas. Acta Neuropathol 122(3):367\u2013369. doi: 10.1007\/s00401-011-0855-6","journal-title":"Acta Neuropathol"},{"issue":"7","key":"1702_CR16","doi-asserted-by":"crossref","first-page":"e101560","DOI":"10.1371\/journal.pone.0101560","volume":"9","author":"C Mian","year":"2014","unstructured":"Mian C, Ceccato F, Barollo S et al (2014) AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. PLoS One 9(7):e101560. doi: 10.1371\/journal.pone.0101560","journal-title":"PLoS One"},{"issue":"3","key":"1702_CR17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2265.2006.02735.x","volume":"66","author":"I Ewing","year":"2007","unstructured":"Ewing I, Pedder-Smith S, Franchi G et al (2007) A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 66(3):348\u2013352","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1702_CR18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","volume":"121","author":"G Schindler","year":"2011","unstructured":"Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397\u2013405. doi: 10.1007\/s00401-011-0802-6","journal-title":"Acta Neuropathol"},{"issue":"21","key":"1702_CR19","first-page":"5954","volume":"60","author":"WA Palmisano","year":"2000","unstructured":"Palmisano WA, Divine KK, Saccomanno G et al (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60(21):5954\u20135958","journal-title":"Cancer Res"},{"issue":"4","key":"1702_CR20","first-page":"793","volume":"59","author":"M Esteller","year":"1999","unstructured":"Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59(4):793\u2013797","journal-title":"Cancer Res"},{"issue":"1","key":"1702_CR21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF03401328","volume":"13","author":"F Ceccato","year":"2014","unstructured":"Ceccato F, Occhi G, Regazzo D et al (2014) Gonadotropin-secreting pituitary adenoma associated with erythrocytosis: case report and literature review. Hormones (Athens) 13(1):131\u2013139","journal-title":"Hormones (Athens)"},{"issue":"10","key":"1702_CR22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0030-1253419","volume":"118","author":"H Bode","year":"2010","unstructured":"Bode H, Seiz M, Lammert A et al (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118(10):760\u2013763. doi: 10.1055\/s-0030-1253419","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"1702_CR23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/cen.12299","volume":"80","author":"M Zilio","year":"2014","unstructured":"Zilio M, Barbot M, Ceccato F et al (2014) Diagnosis and complications of Cushing\u2019s disease: gender-related differences. Clin Endocrinol 80(3):403\u2013410. doi: 10.1111\/cen.12299","journal-title":"Clin Endocrinol"},{"key":"1702_CR24","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.jocn.2009.05.013","volume":"16","author":"S Byrne","year":"2009","unstructured":"Byrne S, Karapetis C, Vrodos N (2009) A novel use of temozolomide in a patient with malignant prolactinoma. J Clin Neurosci 16:1694\u20131696. doi: 10.1016\/j.jocn.2009.05.013","journal-title":"J Clin Neurosci"},{"key":"1702_CR25","doi-asserted-by":"crossref","first-page":"E773-4","DOI":"10.1227\/01.NEU.0000339115.12803.4E","volume":"64","author":"S Mohammed","year":"2009","unstructured":"Mohammed S, Kovacs K, Mason W et al (2009) Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64:E773-4. doi: 10.1227\/01.NEU.0000339115.12803.4E discussion E77425","journal-title":"Neurosurgery"},{"key":"1702_CR26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11102-010-0264-1","volume":"14","author":"TH Dillard","year":"2011","unstructured":"Dillard TH, Gultekin SH, Delashaw JB Jr et al (2011) Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 14:80\u201391. doi: 10.1007\/s11102-010-0264-1","journal-title":"Pituitary"},{"key":"1702_CR27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.14310\/horm.2002.1380","volume":"11","author":"J Phillips","year":"2012","unstructured":"Phillips J, East HE, French SE et al (2012) What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? Horm (Athens) 11:477\u2013482","journal-title":"Horm (Athens)"},{"key":"1702_CR28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/BF03401542","volume":"11","author":"F Rotondo","year":"2012","unstructured":"Rotondo F, Cusimano M, Scheithauer BW et al (2012) Atypical, invasive, recurring crooke cell adenoma of the pituitary. Horm (Athens) 11:94\u2013100","journal-title":"Horm (Athens)"},{"key":"1702_CR29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11102-012-0448-y","volume":"16","author":"I Zemmoura","year":"2013","unstructured":"Zemmoura I, Wierinckx A, Vasiljevic A et al (2013) Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary 16:515\u2013522. doi: 10.1007\/s11102-012-0448-y","journal-title":"Pituitary"},{"issue":"8","key":"1702_CR30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.clineuro.2010.05.003","volume":"112","author":"E Yaman","year":"2010","unstructured":"Yaman E, Buyukberber S, Benekli M et al (2010) Radiation-induced early necrosis in patients with malignant gliomas receiving temozolomide. Clin Neurol Neurosurg 112(8):662\u2013667. doi: 10.1016\/j.clineuro.2010.05.003","journal-title":"Clin Neurol Neurosurg"},{"key":"1702_CR31","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F et al (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95:4592\u20134599","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1702_CR32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ctrv.2012.06.002","volume":"39","author":"Z Tatar","year":"2013","unstructured":"Tatar Z, Thivat E, Planchat E et al (2013) Temozolomide and unusual indications: review of literature. Cancer Treat Rev 39(2):125\u2013135","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1702_CR33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11060-011-0532-6","volume":"104","author":"F Salehi","year":"2011","unstructured":"Salehi F, Scheithauer BW, Kros JM et al (2011) MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol 104(3):647\u2013657. doi: 10.1007\/s11060-011-0532-6","journal-title":"J Neurooncol"},{"issue":"1","key":"1702_CR34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrneurol.2009.197","volume":"6","author":"M Weller","year":"2010","unstructured":"Weller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6(1):39\u201351. doi: 10.1038\/nrneurol.2009.197","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1702_CR35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2265.2006.02545.x","volume":"65","author":"J Lindholm","year":"2006","unstructured":"Lindholm J, Nielsen EH, Bjerre P et al (2006) Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol 65(1):51\u201358","journal-title":"Clin Endocrinol"},{"issue":"11","key":"1702_CR36","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1210\/jc.2009-1097","volume":"94","author":"M Sherlock","year":"2009","unstructured":"Sherlock M, Reulen RC, Alonso AA et al (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94(11):4216\u20134223. doi: 10.1210\/jc.2009-1097","journal-title":"J Clin Endocrinol Metab"},{"key":"1702_CR37","unstructured":"Lombardi G, Rumiato E, Bertorelle R, et al (2013) Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: a prospective study. Am J Clin Oncol. doi: 10.1097\/COC.0b013ec3182a790ea"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1702-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-014-1702-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1702-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T04:48:47Z","timestamp":1566190127000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-014-1702-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,3]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["1702"],"URL":"https:\/\/doi.org\/10.1007\/s11060-014-1702-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,3]]}}}